Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HP-802-247
- Development stage
- Phase 3
- Lead developer
- Healthpoint
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Cell Therapies, Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
HP-802-247 is a cell-based combination product designed for the treatment of chronic wounds, particularly venous leg ulcers. It consists of a fibrinogen solution and a cell preparation containing allogeneic, non-proliferating, living human keratinocytes and fibroblasts delivered in a fibrin matrix by spray application. The mechanism of action involves the release of various growth and angiogenic factors from these metabolically active cells into the wound microenvironment, which stimulates the patient’s own cells to promote healing. Developed as an advanced tissue engineering therapy, it was evaluated in multiple clinical trials for efficacy and safety in chronic venous leg ulcers. The developer/manufacturer is Healthpoint Biotherapeutics.
- Other names
- topical wound spray HP802-247
Beyond the preview
Go deeper on HP-802-247.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HP-802-247.